Next-gen cell therapies for solid tumors: tech-enabled platform discovers selective targets, suppression node modulators.
Joined February 2021
- Tweets88
- Following216
- Followers67
- Likes174
Rubik Therapeutics retweeted
Biotech surge incoming. Lots of exciting science, suppressed valuations, and cash-flush buyers means things are likely to get spicy!
“Every single major pharma company is in shopping mode, right,” @JMaraganore told me
Following the buyouts of Seagen, Prometheus, and Bellus, industry insiders see an M&A wave cresting.
Here's what it means and how it might play out for rest of 2023: endpts.com/biotech-ma-gets-o…
Great to meet you at #AACR23! Exciting work!
We had a great time at #AACR23 this past week. It was a pleasure to have attendees meet our team and engage in open discussions to gain further insight into our posters highlighting Actinium’s work towards targeted radiotherapy R&D. More here: ir.actiniumpharma.com/presen… $ATNM
CAR-T in pediatric neuroblastoma: 63% ORR (17/27) including 33% CR. Wow
🌟Long-awaited proof-of-concept that CAR-T can eradicate solid tumours - and in immune cold paediatric tumours. Brava, Locatelli and Precision Medicine Team at Ospedale Pediatrico Bambino Gesù!
nejm.org/doi/full/10.1056/NE…
Rubik Therapeutics retweeted
Weekend project: Use GPT4 to generate a GUI to control conditional fold generation of RFdiffusion 😎
colab.research.google.com/gi…
Rubik Therapeutics retweeted
Actinium is focused on the development of targeted radiotherapies. Learn more about new data from our HER3 targeting radiotherapy program as well as our novel strategy utilizing Actimab-A to deplete MDSCs by visiting our abstracts ahead of #AACR23: ir.actiniumpharma.com/press-… $ATNM
Rubik Therapeutics retweeted
This is so awesome! Thanks so much for sharing and the awesome description in the Git🥳
It seems like we are more and more shifting from 'how to design' to 'what to design' 💪
Today we're making RF Diffusion, our guided diffusion model for protein design with potential applications in medicine, vaccines & advanced materials, free to use. The software has proven much faster and more capable than prior protein design tools.
bakerlab.org/2023/03/30/rf-d…
Rubik Therapeutics retweeted
The new PSG score is a PSMA-PET Whole-Body Tumor-to-Salivary Gland Ratio to estimate the target expression at the whole body level using the PET MIP to Predict Response to 177Lu-PSMA (PLUVICTO). Tested by 10 international experts on 237 patients. jnm.snmjournals.org/content/…
Been waiting for this--we have a stack of cancer-specific surface targets that need binders
Today we're making RF Diffusion, our guided diffusion model for protein design with potential applications in medicine, vaccines & advanced materials, free to use. The software has proven much faster and more capable than prior protein design tools.
bakerlab.org/2023/03/30/rf-d…
.Thanks @LabCentral @ShaziaMir71 art/science/diversity/compassion! Inspiration hung on the walls. boston25news.com/news/local/…
STEAP2: 2nd priority hit from Owen Witte's '18 surfaceome discovery paper. Broad expression in normal tissue, including lung. Uniformly high in prostate cancer.
SCOOP: $AZN 's first Car-T target revealed (and it's not CD19). Via @evaluatevantage -> evaluate.com/vantage/article…
Another powerful dataset--Cancer Associated Fibroblast scRNAseq--just out. Thanks @simocristea !
Finally, here is the link to the paper @NatureComms
nature.com/articles/s41467-0…
The data compiled here is a valuable resource for #cancer #genomics analyses.
It can also be quite easily further mined & visualized *interactively* via this nice portal:
gist-fgl.github.io/sc-caf-at…
Rubik Therapeutics retweeted
Amazing and inspiring story and first clear evidence of the power of combining gene therapy with cell/immune therapy. It took a lot of courage for both Emily and her family and her doctors @BLLPHD @carlhjune @GruppSteve
Emily Whitehead became the first child to receive genetically-modified T cell to treat her leukemia. Her story helped launch @EWhiteheadFdn and the field of cellular medicine, as told in a new book, #TheSongoftheCell by the Pulitzer Prize-winning, @DrSidMukherjee.
Rubik Therapeutics retweeted
Breaking News! Just in - @JFruehauf awarded the @GalienFdn prize in recognition for commitment to innovation, category for #Innovation, #Accelerators, and #Equity @LabCentral @biolabs 👏 🎉🍾
More + data for solid tumor cell tx @immatics IMA203 anti-PRAME TCR-T: 19-50% cORR (↑dose ↑ORR). 13/32 are melanoma pts, curious about ORR after checkpoint Rx, expect common mechanisms of resistance
Rubik Therapeutics retweeted
The results of different methods applied to the same scRNA-seq data differ substantially.
This is true even for fold changes, as shown below for Seurat and Scanpy.
The differences between selected transcript "markers" are even larger: biorxiv.org/content/10.1101/… via @davisjmcc
Rubik Therapeutics retweeted
Many thanks to all for the kind words today. I'm inspired by all of the inductees this weekend, and the "2022 class". I am honored to be counted among them. Special thanks to my lab, so many wonderful colleagues, mentors, role models, and friends & of course @JeffRathmell 🙏🥰🙌
This Post is from an account that no longer exists. Learn more
Rubik Therapeutics retweeted
FDA creates “Super Office” to manage growing cell and gene therapy workload via @ScienceBoard scienceboard.net/index.aspx?…
h/t vicky arena @BioAleta